Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | LPL | P06858 | 3/20 | 0.57 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1577575 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL28656641 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL19304390 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL2442972 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL9802185 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL2998787 | 0.98 | CYP1A2 (0.60) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| Nitrogen SCHEMBL23668052 | 0.96 | CYP1A2 (0.58) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL417687 | 0.92 | TAAR1 (0.59) | CYP1A2CYP2D6CYP2C19LPLLIPG | |
| SCHEMBL19524669 | 0.90 | TAAR1 (0.65) | CYP1A2CYP2D6CYP2C19TAAR1 | |
| SCHEMBL27390155 | 0.90 | LPL (0.51) | CYP1A2CYP2D6CYP2C19LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100953-A1 | Ligand Compound, Organochromium Compound and Catalyst Composition Comprising the Same | LG CHEM, LTD. (KR) | 2025-03-27 | — | — | US | disclosed |
| EP-4450511-A1 | LIGAND COMPOUND, ORGANIC CHROMIUM COMPOUND AND CATALYST COMPOSITION COMPRISING SAME | LG Chem, Ltd. (KR) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023177129-A1 | LIGAND COMPOUND, ORGANIC CHROMIUM COMPOUND AND CATALYST COMPOSITION COMPRISING SAME | 주식회사 엘지화학 | 2023-09-21 | — | — | WO | disclosed |
| CN-113527341-A | Alkane soluble tetrakis (pentafluorophenyl) borate and preparation method and application thereof | 中国石油天然气股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-1312605-B1 | Method for producing biaryl compounds | SUMITOMO CHEMICAL CO (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-7122711-B2 | Method for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20030158419-A1 | Method for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-08-21 | — | — | US | disclosed |
| EP-1312605-A1 | Method for producing biaryl compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100953-A1 | Ligand Compound, Organochromium Compound and Catalyst Composition Comprising the Same | OXER1, ESR1, NOD1 | CYP1A2 962/4885CYP2D6 1936/4885CYP2C19 1578/4885 |
| US-20030158419-A1 | Method for producing biaryl compound | B2M, BMI1, CYP2W1 | CYP1A2 18/4885CYP2D6 422/4885CYP2C19 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.